MAXIMUS, Inc. (MMS) — Analysis Summary
MAXIMUS, Inc. (MMS) has a market cap of $3.07B with year-over-year revenue growth of +2.4%. Net margin stands at 5.9%. The stock trades at a P/E ratio of 8.2.
Key Takeaways
- Revenue changed +2.4% year-over-year
- Net margin of 5.9%
- P/E ratio of 8.2
Compared to other companies in the SERVICES-BUSINESS SERVICES, NEC sector, MMS posted revenue growth of +2.4% and trades at a P/E of 8.2.
MAXIMUS, Inc. (MMS)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsNo Major Flags
No major credit, margin, or trend red flags were triggered from the latest filings.
Maximus Inc designs, develops, and delivers programs enabling people to access vital government services. It translates health and human services public policy into operating models that achieve outcomes for governments at scale. The company covers a broad array of services, including the operation of large health insurance eligibility and enrollment programs; clinical services, including assessments, appeals, and independent medical reviews; and technology services. The company operates through the following segments: U.S. Federal Services, U.S. Services, and Outside the U.S. A majority of its revenue is derived from the U.S. Federal Services segment, which engages with various U.S. federal government agencies to deliver clinical services, maintenance services, and technology solutions.
Sector
SERVICES-BUSINESS SERVICES, NEC
Employees
37,200
Headquarters
MCLEAN, VA
Exchange
XNYS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Annual Dividend/Share
$1.32
Dividend Yield
2.29%
Dividend History
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.